Successful autologous peripheral blood stem cell transplantation using thiotepa in a patient with systemic sclerosis and cardiac involvement

The Tohoku Journal of Experimental Medicine
Atsushi KomatsudaKen-ichi Sawada

Abstract

A 19-year-old man with systemic sclerosis (SSc) was hospitalized for autologous peripheral blood stem cell transplantation (auto-PBSCT) due to progressive scleroderma and cardiac involvement despite conventional treatment. During the administration of cyclophosphamide (60 mg/kg/day for 2 days) for mobilization and collection of CD34+ selected peripheral blood stem cells, he developed congestive heart failure. Echocardiogram showed hypokinetic asynergy from the septum to posterior wall, which might indicate underlying cardiac damage. We were also concerned about the risk of high-dose cyclophosphamide-induced cardiotoxicity. Since the dose-limiting toxicity of thiotepa, an alkylating agent, is myelosuppression, and cardiac toxicity due to thiotepa is less common, we used a conditioning regimen consisting of thiotepa (10 mg/kg/day, day -5) and low-dose cyclophosphamide (50 mg/kg/day, days -3 and -2), instead of the conventional high-dose cyclophosphamide (50 mg/kg/day x 4 days/course). The post-transplant course was uneventful, and the modified Rodnan skin thickness score improved from 32 to 15. The present case report demonstrates that thiotepa can be employed as a conditioning regimen for auto-PBSCT in SSc patients with cardiac ...Continue Reading

References

Dec 1, 1989·Seminars in Arthritis and Rheumatism·D L JanosikJ Zuckner
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F AversaM F Martelli
Mar 13, 2002·Medicine·Clodoveo FerriUNKNOWN Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc)
May 30, 2002·European Journal of Heart Failure·M I Gharib, A K Burnett
Nov 20, 2002·British Journal of Haematology·Dominique FargeUNKNOWN Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group
Aug 20, 2003·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Y KawabataK Sawada
Jun 10, 2004·Arthritis and Rheumatism·Lazaros I Sakkas, Chris D Platsoucas
Jul 14, 2004·Annals of the Rheumatic Diseases·D FargeUNKNOWN EBMT/EULAR Registry
Aug 27, 2004·The Tohoku Journal of Experimental Medicine·Mitsuru ItohTakashi Uchiyama

❮ Previous
Next ❯

Citations

Aug 24, 2007·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·S B RosaP Pranke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.